Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Gets Price Target Bump from Stifel Nicolaus

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by equities researchers at Stifel Nicolaus from $500.00 to $563.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “hold” rating on the pharmaceutical company’s stock. Stifel Nicolaus‘s target price would indicate a potential upside of 1.78% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Truist Financial upped their price objective on shares of Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on Vertex Pharmaceuticals from $570.00 to $576.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. started coverage on Vertex Pharmaceuticals in a report on Friday, September 11th. They set an “overweight” rating and a $560.00 price target for the company. Finally, UBS Group boosted their price target on shares of Vertex Pharmaceuticals from $585.00 to $615.00 and gave the company a “buy” rating in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $583.04.

Vertex Pharmaceuticals Stock Down 1.0%

Shares of VRTX stock opened at $553.15 on Tuesday. The company has a market capitalization of $140.39 billion, a price-to-earnings ratio of 32.20, a P/E/G ratio of 2.54 and a beta of 0.28. The firm has a fifty day moving average of $523.32 and a 200-day moving average of $479.96. Vertex Pharmaceuticals has a 12-month low of $403.16 and a 12-month high of $568.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The firm’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.80 earnings per share. On average, equities analysts expect that Vertex Pharmaceuticals will post 16.74 EPS for the current year.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Several large investors have recently modified their holdings of VRTX. BlackRock Inc. acquired a new position in Vertex Pharmaceuticals during the second quarter worth about $11,975,849,000. Bank of America Corp DE acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $1,509,651,000. Legal & General Group Plc acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $928,893,000. Bank of New York Mellon Corp acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $830,842,000. Finally, Deutsche Bank AG purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $784,391,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 11.8% year over year to $3.44 billion, exceeding the $3.42 billion analyst estimate. Growth was supported by continued strength in the cystic fibrosis franchise and increasing contributions from newer products, including CASGEVY and JOURNAVX. Vertex Q3 2026 Earnings Call Transcript
• Positive Sentiment: Vertex raised its full-year 2026 revenue guidance, citing broad-based portfolio growth and the successful completion of its Crinetics Pharmaceuticals acquisition. Management also highlighted its advancing pipeline and a developing nephrology franchise as future growth opportunities. Vertex Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The transition from Trikafta to newer cystic fibrosis treatment Alyftrek continued to expand the franchise, while the ramp-up of recently launched medicines may diversify Vertex’s long-term revenue base. However, the company is investing heavily in these launches and in the Crinetics deal. Vertex Spends Its CF Growth on New Launches
• Negative Sentiment: Adjusted earnings were $4.76 per share, below analyst expectations of approximately $4.82–$4.92 and down from $4.80 a year earlier. The shortfall reflects increased spending on new product launches, research and development, and the Crinetics acquisition, limiting profit growth despite higher sales. Vertex Misses Q3 Earnings Estimates
• Negative Sentiment: Although full-year revenue guidance was increased, reports characterized the improvement as a light hike that fell short of some investor expectations. That combination—an earnings miss and limited guidance upside—helped pressure the stock despite the revenue beat. Vertex Yo-Yos on Mixed Third-Quarter Report

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.